Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

被引：0
|
作者：
Fazio, Francesca [1 ]
Di Rocco, Alice [1 ]
Za, Tommaso [2 ]
Tomarchio, Valeria [3 ]
Rago, Angela [4 ]
Piciocchi, Alfonso [5 ]
di Toritto, Tommaso Caravita
Annibali, Ombretta [3 ]
De Stefano, Valerio [2 ]
Foa, Robin [1 ]
Martelli, Maurizio [1 ]
Petrucci, Maria Teresa [1 ]
机构：
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Azienda Osped Policlin Umberto 1, Hematol, Rome, Italy
[2] Catholic Univ, Sect Hematol, Dept Radiol & Hematol Sci, Fdn Policlin A Gemelli, Rome, Italy
[3] Univ Campus Bio Medico, Hematol Unit, Stem Cell Transplantat, Rome, Italy
[4] UOSD Ematol ASL Roma 1, Rome, Italy
[5] Italian Grp Adult Hematol Dis GIMEMA, Rome, Italy
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149547
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3755
引用
收藏
页码：3755 / +
页数：5
相关论文
共 50 条
  • [1] Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy
    Di Rocco, Alice
    Cuneo, Antonio
    Di Rocco, Arianna
    Merli, Francesco
    De Luca, Giulia
    Petrucci, Luigi
    Ansuinelli, Michela
    Penna, Domenico
    Rotondo, Francesco
    Rigolin, Gian Matteo
    Giamo, Mariateresa
    Re, Francesca
    Farcomeni, Alessio
    Martelli, Maurizio
    Foa, Robin
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 828 - 836
  • [2] CAR-T Therapy in Relapsed Refractory Multiple Myeloma
    Ding, Hong
    Wu, Yu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (27) : 4362 - 4382
  • [3] Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Liu, Yang
    Yan, Zhiling
    Wu, Qingyun
    Chen, Chong
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S49
  • [4] Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
    Wu, Weijia
    Ding, Shuyi
    Zhang, Mingming
    Zhou, Yuping
    Sun, Xueshan
    Zhao, Zixuan
    Yang, Yi
    Hu, Yongxian
    Dong, Hengjin
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 701 - 709
  • [5] CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
    Hakan, Goker
    Engin, Kelkitli
    Elifcan, Karakulak Aladag
    Haluk, Demiroglu
    Mehmet, Turgut
    Suman, Kambhampati
    Maxwell, Krem
    FRONTIERS IN MEDICINE, 2024, 11
  • [6] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [7] Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
    Ma, Ruixue
    Zhang, Qi
    Liu, Yang
    Li, Hujun
    Chen, Huimin
    Zhang, Qianqian
    Qiao, Jianlin
    Qi, Kunming
    Shen, Guifang
    Sun, Cai
    Song, Xuguang
    Cao, Jiang
    Cheng, Hai
    Zhu, Feng
    Yan, Zhiling
    Sang, Wei
    Li, Depeng
    Sun, Haiying
    Zheng, Junnian
    Li, Zhenyu
    Xu, Kailin
    Chen, Wei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [8] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
    Gill, Sarvarinder Kaur
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Siegel, David S.
    Parmar, Harsh
    BLOOD, 2023, 142
  • [9] Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
    An, Jing
    Zhao, Jie
    Zou, Ping
    Zhang, Yicheng
    Wei, Junni
    Tian, Weiwei
    Wei, Jia
    CANCER MEDICINE, 2024, 13 (12):
  • [10] CAR T-cell therapy for relapsed or refractory multiple myeloma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
12345